Overview
Cryptococcosis is an infectious disease caused by encapsulated yeast fungi of the genus Cryptococcus, primarily Cryptococcus neoformans and Cryptococcus gattii. It is not a genetic disorder but rather an acquired fungal infection that predominantly affects immunocompromised individuals, particularly those with HIV/AIDS, organ transplant recipients on immunosuppressive therapy, and patients receiving prolonged corticosteroid treatment. However, C. gattii can also cause disease in immunocompetent individuals. The organism is found worldwide in soil, particularly soil contaminated with bird (especially pigeon) droppings, and in association with certain tree species. Cryptococcosis primarily affects the central nervous system and the lungs, though it can disseminate to virtually any organ including the skin, bones, and prostate. The most common and serious manifestation is cryptococcal meningitis (or meningoencephalitis), which presents with headache, fever, neck stiffness, altered mental status, and visual disturbances. Pulmonary cryptococcosis may cause cough, chest pain, and shortness of breath, or may be asymptomatic. Cutaneous involvement can manifest as papules, nodules, or ulcers. Disseminated disease can affect multiple organ systems simultaneously. Treatment depends on the site and severity of infection and the patient's immune status. Cryptococcal meningitis is typically treated with an induction phase of intravenous amphotericin B combined with flucytosine, followed by consolidation and maintenance therapy with fluconazole. Pulmonary or mild-to-moderate disease in immunocompetent patients may be managed with fluconazole alone. In HIV-associated cryptococcosis, antiretroviral therapy is essential but must be carefully timed to avoid immune reconstitution inflammatory syndrome (IRIS). Despite available treatments, cryptococcal meningitis remains a leading cause of death among people living with HIV, particularly in sub-Saharan Africa, with significant global mortality.
Clinical phenotype terms— hover any for plain English:
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
6 eventsUniversity of Minnesota — PHASE2, PHASE3
University of Bucharest — NA
Huashan Hospital — PHASE4
Makerere University — PHASE2, PHASE3
National Institute of Allergy and Infectious Diseases (NIAID)
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Cryptococcosis.
2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Cryptococcosis.
Community
No community posts yet. Be the first to share your experience with Cryptococcosis.
Start the conversation →Latest news about Cryptococcosis
Disease timeline:
New recruiting trial: Vicente Ferrer HIV Cohort Study
A new clinical trial is recruiting patients for Cryptococcosis
New recruiting trial: Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
A new clinical trial is recruiting patients for Cryptococcosis
New recruiting trial: Platform Trial For Cryptococcal Meningitis
A new clinical trial is recruiting patients for Cryptococcosis
New recruiting trial: Fungal Infection Susceptibility
A new clinical trial is recruiting patients for Cryptococcosis
New recruiting trial: Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia
A new clinical trial is recruiting patients for Cryptococcosis
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Cryptococcosis
What is Cryptococcosis?
Cryptococcosis is an infectious disease caused by encapsulated yeast fungi of the genus Cryptococcus, primarily Cryptococcus neoformans and Cryptococcus gattii. It is not a genetic disorder but rather an acquired fungal infection that predominantly affects immunocompromised individuals, particularly those with HIV/AIDS, organ transplant recipients on immunosuppressive therapy, and patients receiving prolonged corticosteroid treatment. However, C. gattii can also cause disease in immunocompetent individuals. The organism is found worldwide in soil, particularly soil contaminated with bird (espe
At what age does Cryptococcosis typically begin?
Typical onset of Cryptococcosis is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Cryptococcosis?
Yes — 2 recruiting clinical trials are currently listed for Cryptococcosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Cryptococcosis?
25 specialists and care centers treating Cryptococcosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.